Hypophosphatemia, which is the primary side effect of Injectafer, occurs when the serum phosphorus levels go below 2.5 mg/Dl. Be aware of symptoms of hypophosphatemia if you receive treatment with Injectafer. An Injectafer lawsuit may allow victims of the potentially deadly side effect to obtain compensation for medical bills and other injury-related damages. Learn about side effects, dosage, and more. Injectafer Lawsuit. Injectafer (ferric carboxymaltose), an injectable form of iron used to treat adult iron deficiency anemia, has been linked to an increased risk for hypophosphatemia (HPP), a severe electrolyte disorder which causes symptoms including muscle weakness, softening of the bones, brain damage, and even death. For you to be able to file a lawsuit and get compensation for the adverse side effects of Injectafer, it should be evident that you suffered the said side effects. Injectafer Problems Caused Chest Pains, Palpitations and Other Symptoms of Severe Hypophosphatemia: Lawsuit July 8, 2020 Written by: Irvin Jackson She suffered symptoms of HPP including: Severe muscle fatigue and weakness, severe fatigue, and severe and extended pain. After getting each dose of Injectafer, your healthcare provider will monitor you for at least 30 minutes. This allows them to manage any side effects that you may have following your dose. Other drugs are available that can treat iron deficiency anemia (IDA). In turn, these hypophosphatemia symptoms can lead to Injectafer-related medical complications including osteomalacia, arrhythmias, cardiac arrest, respiratory failure, and rhabdomyolysis. In December 2018, the Journal of Clinical Investigation published research that linked Injectafer, an injectable iron drug, to the life-threatening condition hypophosphatemia.. Hypophosphatemia occurs when an individual has critically low phosphate levels in their blood. x Symptomatic Hypophosphatemia: Monitor serum phosphate levels in patients at risk for low serum phosphate who require a repeat course of treatment. Some Injectafer users developed these negative symptoms. Some side effects of taking Injectafer commonly occur in people who take the drug, according to Medical News Today. Injectafer is an iron replacement injection used for the treatment of iron deficiency anemia (IDA) since approved by the FDA in 2013. Iron deficiency anemia (IDA) is a prevalent, yet underdiagnosed condition with significant clinical and quality of life impact on patients.1 Symptoms of IDA include It may surprise many to know that Injectafer’s manufacturer, Luitpold Pharmaceuticals, Inc., was aware of the danger for severe hypophosphatemia back in 2007 when the IV treatment was first denied FDA approval. Severe allergic reactions including itching, rashes, hives, wheezing, shock, low blood pressure, lost consciousness, and death. A normal serum phosphate level in the body is considered 2.5 to 4.5 mg/dl. Identifying Symptoms of Hypophosphatemia. Injectafer contains an injectable form of certain types of iron complexes. If you had any of them, you may have had a condition called Severe Hypophosphatemia (Severe HPP).. Furthermore, the clinical trial found that 11.3% of Injectafer patients in the study developed severe hypophosphatemia, compared to zero patients on Monoferric. Several recent studies have indicated that Injectafer, more than other injectable forms of iron, can increase the risk of severe hypophosphatemia (HPP), a condition in which a patient is dangerously low on phosphate. Symptoms of severe HPP … WHAT IS INJECTAFER? When blood testing detects phosphorus below this level, a medical diagnosis of hypophosphatemia (HPP) may be made. Injectafer ® (ferric ... Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in the postmarketing setting. Dizziness, lightheadedness. Introduction. The symptoms include extreme fatigue, cardiac arrest, respiratory failure, heart failure, irregular heart rhythm, coma, and death. Ferric carboxymaltose- (FCM-) related INJECTAFER ® (ferric carboxymaltose injection) Savings Program . • Hypersensitivity Reactions: Observe for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of each administration. Injectafer (ferric carboxymaltose) is a brand-name prescription drug that’s used to treat iron deficiency anemia. https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.12150 In a randomized, double-blinded, controlled trial of adults with iron deficiency anemia from February 2016 to January 2017, we compared rates of hypophosphatemia in response to a single FDA-approved course of ferric carboxymaltose ( n = 1,000) or ferumoxytol ( n = 997). Severe hypophosphatemia is characterized by phosphate levels below 2.0 mg/dL and extreme hypophosphatemia … Symptoms of severe HPP include extreme fatigue, muscle weakness and confusion, and left untreated, severe HPP can cause seizures, respiratory failure, heart failure, rhabdomyolysis, and osteomalacia. 2. Symptoms can include muscle wasting, seizures, respiratory failure, coma, and fatal arrhythmias. Injectafer Hypophosphatemia … If the patient does show early symptoms, the signs are often vague, such as fatigue or irritability. Hypophosphatemia is often not diagnosed in the early stages, even in hospitals. Brittle nails or spooning of the nails. Coldness in extremities. Injectafer-induced hypophosphatemia (HPP) is an Injectafer side effect causing muscle weakness, fatigue, and severe nausea. But for most people who’ve developed hypophosphatemia with Injectafer, the condition resolved within 3 months. Hypophosphatemia seems to mostly occur in people who are already at risk for low ... (5.2) x Hypertension: Monitor patients closely for signs and symptoms of hypertension following each Injectafer administration. Injectafer has been shown to dramatically reduce the amount of phosphate (phosphorus) in the body, leading to severe hypophosphatemia. Kessler received several infusions of Injectafer from 2016 to 2019. (5.1) • Symptomatic Hypophosphatemia: Monitor serum phosphate levels in … Injectafer has been shown to dramatically reduce the amount of phosphate (phosphorus) in the body, leading to severe hypophosphatemia. Hemoglobin is necessary to carry oxygen carrier throughout the body. Injectafer (ferric carboxymaltose injection) is an iron-replacement product administered to adults with anemia.However, recent studies suggest Injectafer is more likely to cause severe hypophosphatemia (dangerously low levels of phosphorous in the blood) compared to other injectable iron supplements. Injectafer infusion side effects may cause drops in phosphate levels in the body, due to impact on the FGF23 (fibroblast growth factor 23) hormone. The more acute or prolonged the hypophosphatemia, the worse symptoms such as extreme fatigue, illness, and muscle weakness can get. Parenteral iron formulations are frequently used to correct iron deficiency anemia (IDA) and iron deficiency (ID). Injectafer FDA Info. Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in the postmarketing setting. In turn, these hypophosphatemia symptoms can lead to Injectafer-related medical complications including osteomalacia, arrhythmias, cardiac arrest, respiratory failure, and rhabdomyolysis. Hypophosphatemia (HPP) Cause by Injectafer Iron Infusion. Injectafer has been around since 2013, when it was approved and released onto the US consumer market. Injectafer-induced hypophosphatemia (HPP) is an Injectafer side effect causing muscle weakness, fatigue, and severe nausea. Injectafer-induced hypophosphatemia (HPP) is an Injectafer side effect causing muscle weakness, fatigue, and severe nausea. If you experienced symptoms of hypophosphatemia—including confusion, weakness, or an irregular heartbeat—following Injectafer therapy, contact us for a complimentary case evaluation. However, no information was provided about potential symptoms of Injectafer causing hypophosphatemia, and the importance of monitoring serum phosphate levels after the iron replacement therapy. Does Injectafer increase the risks of hypophosphatemia? Injectafer has been strongly linked to a shockingly high risk for a very serious side effect: The medical condition hypophosphatemia. In people who develop hypophosphatemia, the phosphate level in the blood falls dangerously low, possibly leading to complications like respiratory failure, seizures, rhabdomyolysis, osteomalacia, heart failure, coma or even death. 2. The injection slowly releases iron directly into the bloodstream to help reduce the side effects and symptoms of iron deficiency anemia. Severe hypophosphatemia is a life-threatening condition. If this is the case, you may be able to claim significant compensation.. Just click any button on this page and answer a few simple questions to check if you can claim. Injectafer Class Action Lawsuit. This can lead to a delayed diagnosis until HPP is severe. Patients might feel weak after the treatment, or experience a rapid or irregular heartbeat. Other signs and symptoms may include 1,8: Weakness. Just the opposite is true: severe hypophosphatemia is incredibly dangerous and can result in long-term damage, or even death. Pica (craving nonfood items such as clay or paper) Injectafer has not been studied or approved for treating symptoms of IDA. Irregular heartbeat. In turn, these hypophosphatemia symptoms can lead to Injectafer-related medical complications including osteomalacia, arrhythmias, cardiac arrest, respiratory failure, and rhabdomyolysis. These cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment. Severe allergic reactions including itching, rashes, hives, wheezing, shock, low blood pressure, lost … Hypophosphatemia goes beyond the mild stage when the body’s level of phosphorous drops below 2.0 mg/dL (moderate) or 1.0 mg/dL (severe). In February 2020, the latest Injectafer label (PDF) was approved by the FDA, which provided added information about the hypophosphatemia risk to the “Warnings and … She suffered from bone pain, severe fatigue and weakness, and shortness of breath and was later diagnosed with HPP. Recent studies suggest Injectafer may be more likely to cause severe hypophosphatemia (dangerously low serum phosphorus levels) compared to other intravenous iron supplements. The Injectafer Savings Program helps patients being treated with Injectafer with their prescription out of pocket responsibility. One very recent clinical study found severe hypophosphatemia occurring in 38.7% of over 1,000 individuals tested who had taken Injectafer, versus a rate of only .4% for individuals who took a competitor product. When mild, it may cause a general feeling of weakness. Injectafer was denied twice by … Possible risk factors for hypophosphatemia include a history of Injectafer Has Been Linked to Severe Hypophosphatemia (HPP) Nausea and irritation at the injection site are common, warned-of, side effects. Injectafer Linked to Severe Hypophosphatemia Studies have linked Injectafer to a dramatically higher risk of HPP compared to other iron injections, such as Monoferric. (5.3) Important Safety Information. These include: 1. Since Injectafer came onto the market, there have been many reports of people receiving the treatment, and then suffering a dangerous condition known as hypophosphatemia (HPP). Many patients do not show symptoms. Intravenous formulation efficacy on ferritin and hemoglobin level improvement is greater than that of oral formulations while they are associated with lower gastrointestinal side effects. Hypophosphatemia is a dangerous, potentially fatal, phosphorous deficiency which, in one study, was apparent in 75% of Injectafer patients. Ferric carboxymaltose- (FCM-) related hypophosphatemia is frequent and appears without clinical significance. The aim of this study was to assess the prevalence, duration, and potential consequences of hypophosphatemia after iron injection. Patients and Methods. In patients with severe hypophosphatemia, abnormally low phosphorous (phosphate) levels in the blood can trigger symptoms like muscle damage, fatigue, bone pain, tooth decay and bone fractures. Fields marked with an * are required. Injectafer Case Evaluation. But most mild cases of hypophosphatemia … Symptoms of hypophosphatemia depend on both the severity and chronicity but may include irritability, fatigue, paraesthesia, proximal myopathy, dysphagia, ileus, and prolonged ventilator dependency in critically ill patients. Prolonged hypophosphatemia and disordered calcium–vitamin D metabolism may also result in osteomalacia. 2 Complications involving severe HPP can even lead … IDA symptoms include dizziness, headache, fatigue, and shortness of breath. More recently, Injectafer has been associated with hypophosphatemia (HPP), potentially leading to other related serious medical complications, such as osteomalacia, arrhythmias, cardiac arrest, respiratory failure, and rhabdomyolysis. Injectafer has been used to rapidly correct anemia, however conclusive to various recent clinical trials, it has been directly linked to Severe Hypophosphatemia as well as weakened bone density. A more severe and unwarned of side effect is Severe Hypophosphatemia (HPP). In cases where hypophosphatemia is caused by a medication, such as Injectafer, the patient is advised to stop taking the drug immediately. Common Injectafer side effectsinclude the following: 1.

Micro Motion Modbus Interface Tool, Double Factorial Table, Wizarding World Candies, Cargo Manifest Form Excel, Benjamin Moore Factory Locations, How To Submit Java Code In Codeforces, Lying About Small Things In A Relationship, Ennis Tx Certificate Of Occupancy, Successful Forex Trading Strategies, What Does Narnia Mean,